Trial Profile

Phase II dose confirmation trial of mocetinostat in combination with azacitidine in patients with myelodysplastic syndromes (MDS).

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mocetinostat (Primary) ; Azacitidine
Indications Myelodysplastic syndromes
Focus Therapeutic Use
Sponsors Mirati Therapeutics

Most Recent Events

15 May 2014 According to a Mirati Therapeutics media release, initial data are expected by the end of 2014.
07 Apr 2014 New trial record
17 Mar 2014 Mirati Therapeutics conducts a phase II dose confirmation trial of mocetinostat in combination with azacitidine in patients with myelodysplastic syndromes, according to a Mirati Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com